Table 5. Clinical, pathological and molecular features of patients according to the LINE-1 methylation levels.
| Clinical, pathological or molecular features | LINE-1≥65% (n = 23) | LINE-1<65% (n = 92) | p-value |
| Sex, n (%) | |||
| Male | 9 (39.1) | 45 (48.9) | 0.4 |
| Female | 14 (60.9) | 47 (51.1) | |
| Mean age (standard deviation)* | 37.65 (8.3) | 37.36 (8.3) | 0.8 |
| Family history of CRC1, n (%) | |||
| Yes | 4 (17.4) | 12 (13) | 0.736 |
| No | 19 (82.6) | 80 (87) | |
| Tumor location, n (%) | |||
| Rectum | 7 (30.4) | 40 (43.5) | 0.209 |
| Distal to splenic flexure | 6 (26.1) | 29 (31.5) | |
| Proximal to splenic flexure | 10 (43.5) | 23 (25) | |
| Synchronous or metachronous CRC, n (%) | |||
| Yes | 3 (13) | 2 (2.2) | 0.054 |
| No | 20 (87) | 90 (97.)8 | |
| TNM tumor stage, n (%) | |||
| I–II | 9 (39.5) | 31 (33.7) | 0.625 |
| III–IV | 14 (60.9) | 61 (66.3) | |
| Tumor differentiation, n (%) | |||
| Well or moderate | 18 (81.8) | 79 (87.8 | 0.489 |
| Poor | 4 (18.2) | 11 (12.2) | |
| Mucinous component, n (%) | |||
| >50% | 14 (60.9) | 25 (27.5) | 0.003 |
| <50% | 9 (39.1) | 66 (72.5) | |
| Medullary growth pattern, n (%) | |||
| Yes | 2 (8.7) | 9 (9.9) | 1 |
| No | 21 (91.3) | 82 (90.1) | |
| Crohńs reaction, n (%) | |||
| Yes | 5 (21.7) | 7 (8) | 0.124 |
| No | 18 (78.3) | 80 (92) | |
| Tumor infiltrating lymphocytes, n (%) | |||
| Yes | 5 (21.7) | 21 (23.9) | 0.83 |
| No | 18 (78.3) | 67 (76.1) | |
| Microsatellite instability, n (%) | |||
| MSI | 6 (26.1) | 19 (20.7) | 0.572 |
| MSS | 17 (73.9) | 73 (79.3) | |
| Mismatch repair deficiency2, n (%) | |||
| Yes | 7 (30.4) | 20 (21.7) | 0.379 |
| No | 16 (69.6) | 72 (78.3) | |
*
P value was calculated by t-test.
1
Including first and second degree relatives.
2
MSI-H and/or loss of expression of MMR proteins by immunohistochemistry.